Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EF-41/KEYNOTE-D58: TTFields + temozolomide with pembrolizumab vs placebo in newly diagnosed glioblastoma
jRCT2011240045Phase 3Recruiting
- Sponsor
- NovoCure
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing TTFields + temozolomide + pembrolizumab with TTFields + temozolomide + placebo (2 arms). Primary endpoint: Overall survival. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2011240045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240045.